$FDMT News

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress

4D Molecular Therapeutics Files Prospectus To Offer And Sell Up To $400M Of Securities In Multiple Offerings

4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35

UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M Estimate

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

4D Molecular Therapeutics Completes Patient Enrollment In 4FRONT-1 Trial Evaluating 4D-150

Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)

Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

4DMT Provides Company Update and Anticipated Development Milestones for 2026